• The FDA allowed the labels for Amgen Inc.'s Vectibix (panitumumab) and Eli Lilly and Co.'s Erbitux (cetuximab) to include retrospective biomarker data showing the drugs do not benefit colon cancer patients with certain KRAS gene mutations.

 

FDA advisers unanimously backed the agency's plan to approve a monovalent nonadjuvanted H1N1 vaccine under a strain change biologics license application supplement without waiting for data from required clinical trials.